Journal article
Real-world evaluation of access-driven Canadian treatment sequences in progressive prostate cancer (REACTIVATE).
Abstract
INTRODUCTION: The results of the phase 3 ALSYMPCA trial showed that Radium-223 (Ra-223) improves overall survival (OS) and delays onset of first symptomatic skeletal event vs. placebo in patients with metastatic castration-resistant prostate cancer (mCRPC). The purpose of the REACTIVATE study was to inform the optimal placement of Ra-233 in the treatment sequence by evaluating clinical outcomes and healthcare resource utilization using …
Authors
Ko JJ; Mbuagbaw L; Tyldesley S; Lowther J; Sunderland K; Royer C; Faure M; MacPhail C; Faizi S; Cheung WY
Journal
Canadian Urological Association Journal, Vol. 18, No. 7, pp. e194–e203
Publication Date
July 2024
DOI
10.5489/cuaj8620
ISSN
1911-6470